GSK and Genmab announce positive interim result for phase III study of ofatumumab as maintenance therapy for relapsed CLL
Issued: 31 July 2014, London UK GlaxoSmithKline plc (LSE/NYSE: GSK) and Genmab A/S (OMX: GEN) announced today that an Independent Data Monitoring Committee (IDMC) interim analysis of a phase III study, PROLONG (OMB 112517), reached the predefined …